EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy

Francesca Palandri, Filippo Branzanti, Erika Morsia, Alessandra Dedola, Giulia Benevolo, Mario Tiribelli, Eloise Beggiato, Mirko Farina, Bruno Martino, Giovanni Caocci, Novella Pugliese, Alessia Tieghi und 18 weitere

Annals of Hematology · 2025

DOI: 10.1007/s00277-025-06204-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, 2025. Verfasst von Francesca Palandri und 29 weiteren Autor:innen. Beteiligte Einrichtung: IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. francesca.palandri@unibo.it. Hauptthemen laut MEDLINE: Calreticulin, Mutation, Primary Myelofibrosis, Pyrazoles. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alma Mater Studiorum - Università di Bologna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Calreticulin ( CALR ) mutations are detected in around 20% of patients with primary and post-essential thrombocythemia myelofibrosis (MF). Regardless of driver mutations, patients with splenomegaly and symptoms are generally treated with JAK2 -inhibitors, most commonly ruxolitinib. Recently, new therapies specifically targeting the CALR mutant clone have entered clinical investigation. To collect information on efficacy and safety of ruxolitinib in CALR -mutated patients, we report a sub-analysis of the “RUX-MF” (NCT06516406) study, comprising 135 CALR -mutated and 786 JAK2 -mutated ruxolitinib-treated patients. Compared to JAK2 -mutated patients, CALR -mutated patients started ruxolitinib with a more severe disease (higher peripheral blast counts, lower hemoglobin levels and worse marrow fibrosis) and after a longer median time from diagnosis (2.6 versus 0.7 years, p < 0.001). At 6 months, spleen responses were numerically inferior in CALR -mutated patients, who also had significantly lower rates of symptom responses (56.1% versus 66.7%, p = 0.04).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CalreticulinMutationPrimary MyelofibrosisPyrazolesAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedJanus Kinase 2NitrilesPyrimidinesSurvival RateTreatment Outcome

Stichwörter der Autor:innen

CALR mutationJAK2 mutationMyelofibrosisMyeloproliferative neoplasmsRuxolitinib

Substanzen

CALR protein, humanCalreticulinJAK2 protein, humanJanus Kinase 2NitrilesPyrazolesPyrimidinesruxolitinib

Autor:innen und Institutionen

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy. francesca.palandri@unibo.it.
  • Institute of Hematology "L. and A. Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Massarenti 9, Bologna (BO), 40138, Italy. francesca.palandri@unibo.it.
  • Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy.
  • Hematology Unit, Department of Clinical and Molecular Sciences, DISCLIMO, Università Politecnica Delle Marche, Ancona, Italy.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli", Bologna, Italy.
  • University Hematology Division, Città della Salute e Della Scienza Hospital, Torino, Italy.

Förderung

  • Alma Mater Studiorum - Università di Bologna

Zitieren

APA

Palandri, F., Branzanti, F., Morsia, E., Dedola, A., Benevolo, G., Tiribelli, M., Beggiato, E., Farina, M., Martino, B., Caocci, G., Pugliese, N., Tieghi, A., Crugnola, M., Binotto, G., Cavazzini, F., Abruzzese, E., Isidori, A., Scalzulli, E., D'Agostino, D., …, & Bonifacio, M. (2025). Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy. Annals of Hematology. https://doi.org/10.1007/s00277-025-06204-5

Vancouver

Palandri F, Branzanti F, Morsia E, Dedola A, Benevolo G, Tiribelli M, et al. Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy. Annals of Hematology. 2025. doi:10.1007/s00277-025-06204-5

BibTeX
@article{Palandri2025,
  author = {Palandri, Francesca and Branzanti, Filippo and Morsia, Erika and Dedola, Alessandra and Benevolo, Giulia and Tiribelli, Mario and Beggiato, Eloise and Farina, Mirko and Martino, Bruno and Caocci, Giovanni and Pugliese, Novella and Tieghi, Alessia and Crugnola, Monica and Binotto, Gianni and Cavazzini, Francesco and Abruzzese, Elisabetta and Isidori, Alessandro and Scalzulli, Emilia and D'Agostino, Domenico and Caserta, Santino and Nardo, Antonella and Lemoli, Roberto Massimo and Cilloni, Daniela and Bocchia, Monica and Pane, Fabrizio and Heidel, Florian H and Palumbo, Giuseppe A and Breccia, Massimo and Elli, Elena M and Bonifacio, Massimiliano},
  title = {Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy},
  journal = {Annals of Hematology},
  year = {2025},
  doi = {10.1007/s00277-025-06204-5}
}
Kostenlos starten →